Placental transfer dynamics and durability of maternal COVID-19 vaccine-induced antibodies in infants
Paola A. Lopez, Nadège Nziza, Tina Chen, Lydia L. Shook, Madeleine D. Burns, Stepan Demidkin, Olyvia Jasset, Babatunde Akinwunmi, Lael M. Yonker, Kathryn J. Gray, Michal A. Elovitz, Douglas A. Lauffenburger, Boris Jülg, Andrea G. Edlow
Abstract
Completion of a COVID-19 vaccination series during pregnancy effectively reduces COVID-19 hospitalization among infants less than 6 months of age. The dynamics of transplacental transfer of maternal vaccine-induced antibodies, and their persistence in infants at 2, 6, 9, and 12 months, have implications for new vaccine development and optimal timing of vaccine administration in pregnancy. We evaluated anti-COVID antibody IgG subclass, Fc-receptor binding profile, and activity against wild-type Spike and RBD plus five variants of concern (VOCs) in 153 serum samples from 100 infants. Maternal IgG1 and IgG3 responses persisted in 2- and 6-month infants to a greater extent than the other IgG subclasses, with high persistence of antibodies binding placental neonatal Fc-receptor and FcγR3A. Lowest persistence was observed against the Omicron RBD-specific region. Maternal vaccine timing, placental Fc-receptor binding capabilities, antibody subclass, fetal sex, and VOC all impact the persistence of antibodies in infants through 12 months of age.